Mitomycin-C plus a 3-day continuous intravenous infusion of 5- fluorouracil: An inactive salvage regimen for platinum-resistant ovarian carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Ovarian Neoplasms
  • Platinum
  • Salvage Therapy

abstract

  • In a Phase II trial, patients with refractory ovarian cancer were given 10 mg/m2 mitomycin-C i.v. every 8 weeks and 1000 mg/m2/day 5-fluorouracil for 3 consecutive days by continuous intravenous infusion repeated every 4 weeks. Sixteen heavily pretreated patients with platinum-resistant disease were treated and no major responses were observed. Only 2 patients required subsequent dose reduction for myelotoxicity. No sign of gastrointestinal toxicity was seen. This regimen is inactive as salvage treatment for refractory ovarian cancer.

publication date

  • January 1993

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1006/gyno.1993.1159

PubMed ID

  • 8349161

Additional Document Info

start page

  • 30

end page

  • 3

volume

  • 50

number

  • 1